ReviewCurrent oncology reports2003
Barrett's esophagus and Barrett's carcinoma.
Review in Current oncology reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Barrett oesophagus: lessons on its origins from the lesion itself.Nature reviews. Gastroenterology & hepatology · 2015Review
- Risk factors for neoplastic progression in Barrett's esophagus.World journal of gastroenterology · 2011Review
- Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus.BMC cancer · 2008Article
- Surgical management of esophagogastric junction tumors.World journal of gastroenterology · 2006Review
- Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis.Oncogene · 2006Article
- Survival after oesophagectomy for cancer of the oesophagus.Langenbeck's archives of surgery · 2005Review
- Carcinoma of the cardia: classification as esophageal or gastric cancer?International journal of colorectal disease · 2005Review
- Activation of NFkappaB represents the central event in the neoplastic progression associated with Barrett's esophagus: a possible link to the inflammation and overexpression of COX-2, PPARgamma and growth factors.Digestive diseases and sciences · 2004Article
- Improved prognosis of resected esophageal cancer.World journal of surgery · 2004Article
- The treatment of Barrett's esophagus.Journal of medicine and lifeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The alarming rise in the incidence of esophageal adenocarcinomas in the Western world has focused interest on so-called Barrett's esophagus. Barrett's esophagus is characterized by specialized intestinal epithelium replacing the normal squamous epithelium in the distal esophagus and is considered a consequence of long-lasting and severe gastroesophageal reflux disease. A metaplasia-dysplasia-carcinoma sequence links Barrett's esophagus with adenocarcinoma of the distal esophagus (Barrett's cancer). Despite intensive research, many questions concerning the pathogenesis, diagnosis, and treatment of Barrett's esophagus and associated adenocarcinoma are still unanswered. Based on current data, the malignant progression of Barrett's esophagus cannot be substantially prevented by medical or surgical therapy for reflux. Although no firm data are available to show that surveillance strategies can reduce overall mortality from Barrett's cancer, early detection and cure are possible. Management of Barrett's esophagus and carcinoma is reviewed with reference to the sequence of disease from metaplasia to carcinoma.
Indexed as
Identifiers
12667417What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.